Bevacizumab Hanbeitai Biosimilar Is Approved By The National Medical Products Administration

Henlius biological room: Hanbeitai bevacizumab biosimilar is approved by the National Administration of Medical Products

Shanghai PRNewswire / - Shanghai Henlius Biotech, Inc. (2696.HK) has announced that the bevacizumab Hanbeitai biosimilar, independently developed and manufactured by Henlius, has been approved by the National Products Administration Physicians (NMPA). It is indicated for the treatment of metastatic colorectal cancer (mCRC) and unresectable, locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Hanbeitai is the company's fourth monoclonal antibody (mAb) approved in China , following the rituximab Hanlikang biosimilar, the trastuzumab Hanquyou biosimilar (Zercepac ^Ⓡin the EU) and the adalimumab biosimilar Handayuan. The product portfolio has been completed with a greater coverage of indications that includes hematological neoplasms, solid tumors, autoimmune diseases, etc.

Wenjie Zhang , Chairman, CEO and CEO of Henlius, said, "We are very pleased that Hanbeitai has been approved as our fourth product. The credit goes to all the healthcare professionals, patients and regulatory authorities who have contributed to the studies of Hanbeitai. As we maximize the value of biosimilar medicines, we will continue to advance the process of clinical trials of their combination with proprietary immunotherapy products, such as serplulimab, and grow to become a more innovative global biopharmaceutical company. "

Jason Zhu , Chairman of Henlius, said: "Lung cancer and colorectal cancer rank second and third in the highest incidence of cancers in the world, respectively. They also rank first and second in China , and there is a huge treatment demand. Similarity studies did not show statistically significant differences in efficacy, and safety is very similar to that of the original. It is believed that the approval of Hanbeitai will further improve the accessibility of bevacizumab and provide a discharge option quality for lung cancer and colorectal cancer patients. "

www.henlius.com